Skip to Content

Generic Eskata Availability

Eskata is a brand name of hydrogen peroxide topical, approved by the FDA in the following formulation(s):

ESKATA (hydrogen peroxide - solution;topical)

  • Manufacturer: ACLARIS THERAPS INC
    Approval date: December 14, 2017
    Strength(s): 40% [RLD]

Has a generic version of Eskata been approved?

No. There is currently no therapeutically equivalent version of Eskata available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eskata. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Seborrheic keratosis treatment
    Patent 7,381,427
    Issued: June 3, 2008
    Inventor(s): Ancira; Margaret & Miller; Mickey

    The subject of the present invention is seborrheic keratosis removal and prevention utilizing safe dependable effective biocompatible treatments with no scarring, bleeding, burning, freezing, shocking, and hypopigmentation or hyperpigmentation.

    Patent expiration dates:

    • June 8, 2022
      ✓ 
      Patent use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
  • Peroxide formulations and methods and applicators for using the same
    Patent 9,675,639
    Issued: June 13, 2017
    Assignee(s): ACLARIS THERAPEUTICS, INC.

    Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

    Patent expiration dates:

    • July 4, 2035
      ✓ 
      Patent use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
      ✓ 
      Drug product
  • Peroxide formulations and methods and applicators for using the same
    Patent 9,980,983
    Issued: May 29, 2018
    Assignee(s): ACLARIS THERAPEUTICS, INC.

    Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

    Patent expiration dates:

    • April 21, 2035
      ✓ 
      Patent use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • December 14, 2020 - NEW PRODUCT

More about Eskata (hydrogen peroxide topical)

Consumer resources

Other brands: Proxacol

Professional resources

Related treatment guides

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide